39.45
price down icon1.37%   -0.55
after-market After Hours: 39.45
loading
Moonlake Immunotherapeutics stock is traded at $39.45, with a volume of 385.32K. It is down -1.37% in the last 24 hours and down -1.67% over the past month. MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.
See More
Previous Close:
$40.00
Open:
$40.33
24h Volume:
385.32K
Relative Volume:
0.92
Market Cap:
$2.33B
Revenue:
-
Net Income/Loss:
$-80.77M
P/E Ratio:
-31.06
EPS:
-1.27
Net Cash Flow:
$-80.80M
1W Performance:
+7.29%
1M Performance:
-1.67%
6M Performance:
-17.81%
1Y Performance:
-3.83%
1-Day Range:
Value
$38.71
$40.97
1-Week Range:
Value
$35.98
$40.97
52-Week Range:
Value
$31.42
$58.26

Moonlake Immunotherapeutics Stock (MLTX) Company Profile

Name
Name
Moonlake Immunotherapeutics
Name
Phone
41 41 510 8022
Name
Address
DORFSTRASSE 29, ZUG
Name
Employee
100
Name
Twitter
Name
Next Earnings Date
2024-11-12
Name
Latest SEC Filings
Name
MLTX's Discussions on Twitter

Compare MLTX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
MLTX
Moonlake Immunotherapeutics
39.45 2.33B 0 -80.77M -80.80M -1.27
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
490.47 128.67B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
585.49 60.99B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
599.87 36.96B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
236.75 29.89B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
252.77 25.74B 3.81B -644.79M -669.77M -6.24

Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-18-25 Initiated RBC Capital Mkts Outperform
Jan-17-25 Upgrade Goldman Neutral → Buy
Nov-05-24 Resumed Wedbush Outperform
Aug-26-24 Downgrade Wolfe Research Outperform → Peer Perform
Jun-25-24 Initiated Oppenheimer Outperform
Apr-02-24 Initiated Goldman Neutral
Feb-15-24 Initiated Wolfe Research Outperform
Dec-08-23 Initiated Citigroup Buy
Nov-02-23 Initiated Stifel Buy
Sep-14-23 Downgrade Bryan Garnier Buy → Neutral
Aug-31-23 Initiated Needham Buy
Jun-15-23 Initiated Barclays Equal Weight
May-01-23 Initiated Guggenheim Buy
Mar-22-23 Initiated Wedbush Outperform
Mar-09-23 Initiated BTIG Research Buy
Feb-14-23 Initiated Cantor Fitzgerald Overweight
Feb-02-23 Initiated Bryan Garnier Buy
Nov-11-22 Initiated Jefferies Buy
Aug-25-22 Initiated SVB Leerink Outperform
Jul-21-22 Initiated H.C. Wainwright Buy
Jul-07-22 Initiated Cowen Outperform
View All

Moonlake Immunotherapeutics Stock (MLTX) Latest News

pulisher
Apr 21, 2025

11 Best Guru Stocks to Buy According to Wall Street Analysts - Insider Monkey

Apr 21, 2025
pulisher
Apr 17, 2025

(MLTX) On The My Stocks Page - news.stocktradersdaily.com

Apr 17, 2025
pulisher
Apr 14, 2025

Psoriasis Market Outlook in the 7MM Through 2034: In-Depth Analysis by Psoriasis Type | DelveInsight - GlobeNewswire Inc.

Apr 14, 2025
pulisher
Apr 09, 2025

We Think MoonLake Immunotherapeutics (NASDAQ:MLTX) Can Afford To Drive Business Growth - simplywall.st

Apr 09, 2025
pulisher
Apr 08, 2025

Oversold Conditions For MoonLake Immunotherapeutics (MLTX) - Nasdaq

Apr 08, 2025
pulisher
Apr 08, 2025

4,500 Shares in MoonLake Immunotherapeutics (NASDAQ:MLTX) Purchased by KLP Kapitalforvaltning AS - Defense World

Apr 08, 2025
pulisher
Apr 08, 2025

Sei Investments Co. Acquires 1,202 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World

Apr 08, 2025
pulisher
Apr 08, 2025

MoonLake Immunotherapeutics (NASDAQ:MLTX) Sets New 1-Year Low – Here’s What Happened - Defense World

Apr 08, 2025
pulisher
Apr 08, 2025

MoonLake Immunotherapeutics: A Buy At Dips (NASDAQ:MLTX) - Seeking Alpha

Apr 08, 2025
pulisher
Apr 07, 2025

MoonLake Immunotherapeutics’ $500 Million Debt Financing with Hercules Capital - Global Legal Chronicle

Apr 07, 2025
pulisher
Apr 04, 2025

Cantor Fitzgerald maintains Overweight on Moonlake stock - Investing.com Australia

Apr 04, 2025
pulisher
Apr 04, 2025

MoonLake secures up to $500 million financing; research update - The Pharma Letter

Apr 04, 2025
pulisher
Apr 04, 2025

Cantor Fitzgerald maintains Overweight on Moonlake stock By Investing.com - Investing.com Canada

Apr 04, 2025
pulisher
Apr 04, 2025

MoonLake secures $500m for lead drug, plus other financings - Pharmaphorum

Apr 04, 2025
pulisher
Apr 04, 2025

Switzerland: MoonLake secures up to US$500m in non-dilutive financing - Investors in Healthcare

Apr 04, 2025
pulisher
Apr 04, 2025

MoonLake in US$500m debt deal with Hercules Capital - European Biotechnology Magazine

Apr 04, 2025
pulisher
Apr 03, 2025

MoonLake secures up to $500M in financing from Hercules Capital - MSN

Apr 03, 2025
pulisher
Apr 03, 2025

MoonLake discloses up to $500M in financing; OSR’s deal with innovation fund - Endpoints News

Apr 03, 2025
pulisher
Apr 03, 2025

MoonLake Obtains $500 Million Facility From Hercules Capital - MarketScreener

Apr 03, 2025
pulisher
Apr 03, 2025

MoonLake secures hefty financing package to fuel sonelokimab's path to market - FirstWord

Apr 03, 2025
pulisher
Apr 03, 2025

MoonLake Immunotherapeutics secures up to $500M in non-dilutive financing - TipRanks

Apr 03, 2025
pulisher
Apr 03, 2025

MoonLake Immunotherapeutics Secures $500M Financing for Growth - TipRanks

Apr 03, 2025
pulisher
Apr 03, 2025

Moonlake Secures Up To $500 Million In Non-Dilutive Financing From Hercules Capital And Announces A Capital Markets Update On April 29 To Provide Important Clinical Updates - MarketScreener

Apr 03, 2025
pulisher
Apr 03, 2025

MoonLake Secures up to $500 Million in Non-Dilutive - GlobeNewswire

Apr 03, 2025
pulisher
Apr 03, 2025

MoonLake Lands Massive $500M Deal: Game-Changing Clinical Updates Coming April 29 - Stock Titan

Apr 03, 2025
pulisher
Apr 02, 2025

MoonLake (MLTX) Secures $500M Non-Dilutive Financing to Advance Sonelokimab - GuruFocus

Apr 02, 2025
pulisher
Apr 01, 2025

How the (MLTX) price action is used to our Advantage - news.stocktradersdaily.com

Apr 01, 2025
pulisher
Apr 01, 2025

Teacher Retirement System of Texas Has $354,000 Holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World

Apr 01, 2025
pulisher
Mar 31, 2025

MoonLake’s 37% decline validates InvestingPro’s overvaluation warning By Investing.com - Investing.com Australia

Mar 31, 2025
pulisher
Mar 28, 2025

MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Rating of “Buy” from Analysts - Defense World

Mar 28, 2025
pulisher
Mar 22, 2025

Long Term Trading Analysis for (MLTX) - Stock Traders Daily

Mar 22, 2025
pulisher
Mar 20, 2025

MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Bought by PNC Financial Services Group Inc. - Defense World

Mar 20, 2025
pulisher
Mar 20, 2025

PNC Financial Services Group Inc. Increases Stock Position in MoonLake Immunotherapeutics (NASDAQ:MLTX) - The AM Reporter

Mar 20, 2025
pulisher
Mar 19, 2025

BTIG maintains Moonlake stock Buy rating and $81 target By Investing.com - Investing.com Australia

Mar 19, 2025
pulisher
Mar 19, 2025

MoonLake Immunotherapeutics’ Sonelokimab Positioned as Leading Treatment for Hidradenitis Suppurativa Amidst Weak JAK Inhibitor Competition - TipRanks

Mar 19, 2025
pulisher
Mar 19, 2025

BTIG maintains Moonlake stock Buy rating and $81 target - Investing.com

Mar 19, 2025
pulisher
Mar 19, 2025

MoonLake Immunotherapeutics (NASDAQ:MLTX) Coverage Initiated by Analysts at Royal Bank of Canada - Defense World

Mar 19, 2025
pulisher
Mar 18, 2025

MoonLake earns new Outperform at RBC Capital Markets on lead drug - MSN

Mar 18, 2025
pulisher
Mar 18, 2025

RBC Capital Initiates Coverage of MoonLake Immunotherapeutics (MLTX) with Outperform Recommendation - Nasdaq

Mar 18, 2025
pulisher
Mar 18, 2025

MoonLake stock earns new Outperform at RBC (MLTX:NASDAQ) - Seeking Alpha

Mar 18, 2025
pulisher
Mar 18, 2025

Why MoonLake Immunotherapeutics Shares Are Rising - TipRanks

Mar 18, 2025
pulisher
Mar 18, 2025

Goldman Sachs Thinks Mid-Cap Biotech MoonLake Could Soar Over 80%: Is Retail Watching Closely? - MSN

Mar 18, 2025
pulisher
Mar 18, 2025

Guggenheim maintains $80 target on Moonlake Immunotherapeutics stock - Investing.com

Mar 18, 2025
pulisher
Mar 18, 2025

MoonLake Immunotherapeutics initiated with an Outperform at RBC Capital - TipRanks

Mar 18, 2025
pulisher
Mar 18, 2025

Correction: RBC Initiates MoonLake Immunotherapeutics at Outperform, Speculative Risk With $67 Price Target - MarketScreener

Mar 18, 2025
pulisher
Mar 18, 2025

RBC Initiates MoonLake Immunotherapeutics at Outperform, Speculative Risk With $17 Price Target - Marketscreener.com

Mar 18, 2025
pulisher
Mar 17, 2025

MoonLake Immunotherapeutics: Advancing Sonelokimab with Promising Phase III VELA Program and Favorable Market Positioning - TipRanks

Mar 17, 2025
pulisher
Mar 15, 2025

MoonLake Immunotherapeutics Advances Clinical Trials in 2024 - TipRanks

Mar 15, 2025
pulisher
Mar 14, 2025

MoonLake’s CEO on its looming mid-year pivotal readout in skin disease - Endpoints News

Mar 14, 2025
pulisher
Mar 14, 2025

MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Sold by Victory Capital Management Inc. - Defense World

Mar 14, 2025
pulisher
Mar 12, 2025

Cowen maintains Buy on Moonlake Immunotherapeutics stock By Investing.com - Investing.com Australia

Mar 12, 2025

Moonlake Immunotherapeutics Stock (MLTX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.27
price up icon 1.00%
$71.24
price up icon 2.49%
$32.19
price up icon 0.00%
$27.35
price up icon 8.45%
$104.68
price up icon 2.82%
biotechnology ONC
$252.77
price up icon 10.27%
Cap:     |  Volume (24h):